You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

835 Results
Document
New
Jun 2025
Document
New
Jun 2025
Statistical Reports
Jun 2016
Statistical Reports
Jan 2018
Statistical Reports
Aug 2020
Statistical Reports
Nov 2022
Document
New
Jul 2025
Document
New
Jul 2025
Document
New
Jul 2025
Document
New
Jul 2025
Drug
Other Name(s): Xtandi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration-sensitive prostate cancer (mCSPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enzalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025

Pages